Klinger Shannon Thyme, Chief Legal Officer of Moderna (MRNA), has filed 40 Form 4 transactions over the past several months, all tied to a single issuer. The pattern is uniformly one-sided: zero open-market purchases, zero acquisitions, and roughly $899,597 in total sales value. The two most recent open-market sales occurred on June 4, 2026, netting $173,550, and on March 2, 2026, for $726,047. These sales were paired with option exercises (coded M) on the same dates, including a $429,880 exercise value in March and a $107,462 exercise in June, indicating the shares sold were sourced from vested equity rather than newly acquired positions.
The remaining activity consists almost entirely of automatic, non-discretionary transactions: shares withheld to cover tax obligations (coded F) and zero-value option exercises (coded M). These F-trades, ranging from $5,843 on February 27, 2026, to $329,691 on March 5, 2026, are standard payroll-like deductions triggered by vesting events, not signals of conviction. Two grant awards (coded A) on March 1, 2026, also carried no cash value. The absence of any P-coded purchases—the only code indicating a voluntary, open-market buy—reinforces that Thyme has been a consistent net seller, though the sales are mechanically tied to equity compensation cycles rather than discretionary portfolio shifts.
Across the filing window, the trajectory is steady liquidation of vested Moderna stock, with the largest single sale in early March and a smaller follow-up in early June. The dollar values are substantial but proportionate to a senior executive’s compensation package, and the interleaving of M and F codes with each S transaction suggests a routine exercise-and-sell pattern. No recent buys or acquisitions appear in the data, leaving the insider’s directional bias as clearly bearish in terms of cash flow, though the absence of open-market purchases is typical for executives who receive equity as part of their pay.
AI-assisted summary